ஈகர்ட் வீம்மேர் இல் ஸ்டோனி சிற்றாறு பல்கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஈகர்ட் வீம்மேர் இல் ஸ்டோனி சிற்றாறு பல்கலைக்கழகம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஈகர்ட் வீம்மேர் இல் ஸ்டோனி சிற்றாறு பல்கலைக்கழகம் Today - Breaking & Trending Today

Codagenix Appoints Johanna Kaufmann, Ph.D., Executive Vice President, Oncology to Lead Customization of Oncolytic Viruses for Solid Tumors

/PRNewswire/ Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies for cancer, today. ....

United States , Baden Wüberg , United Kingdom , Johanna Bennett Ingrid Mezo , Johanna Kaufmann , Robert Coleman , Helmholtz University Group , Eckard Wimmer At Stony Brook University , Harvard Medical School , Tesaro Inc In Waltham , National Academy Of Science , German Cancer Research Center , Department Of Neurosurgery , Prnewswire Codagenix Inc , Automation Vaccine Development At Genocea Biosciences , Codagenix Inc , Executive Vice President , Synthetic Attenuated Virus Engineering , Scientific Director , Senior Scientist , Vaccine Development , Genocea Biosciences , Harvey Cushing Neuro Oncology Laboratories , Molecular Medicine , National Academy , Eckard Wimmer ,

Codagenix Appoints Linda Maldonado as VP, Biologics Chemistry and Manufacturing Controls

Codagenix Appoints Linda Maldonado as VP, Biologics Chemistry and Manufacturing Controls
Ms. Maldonado to Oversee Manufacturing Development of Codagenix s Vaccines as Clinical Trials for COVID-19, RSV and Flu Progress
News provided by
Share this article
Share this article
FARMINGDALE, N.Y., April 14, 2021 /PRNewswire/ Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the appointment of biotech industry veteran Linda Maldonado as Vice President, Biologics Chemistry and Manufacturing Controls (CMC).
We are pleased to welcome Linda to Codagenix s growing management team in anticipation of multiple significant growth opportunities this year, including the advancement COVI-VAC, our single-dose, intranasal, live-attenuated COVID-19 vaccine, to late-stage clinical trials, said J. Robert Coleman, Ph.D., CEO of Codagenix. Linda has a proven track record with clinical process ....

Sanofi Pasteur , Baxter Bioscience , Johanna Bennett Ingrid Mezo , Robert Coleman , Eckard Wimmer At Stony Brook University , Human Genome Sciences , Bloomsburg University , Stroudsburg University , National Academy Of Science , Codagenix Inc , Linda Maldonado , Vice President , Biologics Chemistry , Manufacturing Controls , Synthetic Attenuated Virus Engineering , Senior Director , Fill Finish , Catalent Cell , Gene Therapy , East Stroudsburg University , National Academy , Eckard Wimmer , Stony Brook University , Adjuvant Capital , Topspin Partners , சனோஃபி பாஸ்டர் ,

Codagenix Expands Senior Management Team With Three New Appointments

Codagenix Expands Senior Management Team With Three New Appointments
New Hires Bolster Codagenix s Operations, Regulatory Affairs and Clinical Trial Management
News provided by
Share this article
Share this article
NEW YORK, March 17, 2021 /PRNewswire/ Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the expansion of its senior management team with three new appointments. Lisa Runco, Ph.D., has been named Director of Operations. Additionally, Sally Yang, M.S., R.A.C. has been appointed Associate Director of Regulatory Affairs, and Lasmy Tea, M.S., M.P.H., has been named Associate Director of Clinical Project Management. ....

Salt Lake City , United States , Lisa Runco , Johanna Bennett Ingrid Mezo , Robert Coleman , Sally Yang , Regulatory Program Management At Synchrogenix , Advisory Committee , York Institute Of Technology , York University , Clinical Network Services , Codagenix Inc , Eckard Wimmer At Stony Brook University , Regulatory Affairs , Drug Administration , Global Public Health , National Academy Of Science , Columbia University , Research Core , Stony Brook University , Regulatory Affairs Certification , Keck Graduate Institute , Huntsman Cancer Center , Associate Director , Lasmy Tea , Clinical Project ,

Codagenix Secures U.S. Patent for Codon-Deoptimized RSV Vaccine Candidates

Share this article
Share this article
NEW YORK, Jan. 26, 2021 /PRNewswire/ Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the issuance of a patent for a vaccine focused on human codon-deoptimized respiratory syncytial viruses (RSV) vaccine. Codagenix currently holds the exclusive license to this patent. The issuance of US Patent No. 10,695,414 broadens Codagenix s intellectual property portfolio, covering human codon deoptimization of the RSV F and/or G proteins of in a live-attenauted vaccine.
Codagenix is currently investigating its live attenuated CodaVax™-RSV vaccine, an intranasally-administered vaccine for the prevention of RSV, in a randomized, double-blind, placebo-controlled Phase 1 clinical trial. Top line data from trial, which is designed to evaluate the safety, tolerability and immunogenicity of CodaVax ....

Johanna Bennett Ingrid Mezo , J Robert Coleman , Centers For Disease , Eckard Wimmer At Stony Brook University , Prnewswire Codagenix Inc , National Academy Of Science , Codagenix Inc , Synthetic Attenuated Virus Engineering , Respiratory Syncytial Virus , National Academy , Eckard Wimmer , Stony Brook University , Adjuvant Capital , Topspin Partners , Disease Control , ஜு ராபர்ட் கோல்மேன் , மையங்கள் க்கு நோய் , ஈகர்ட் வீம்மேர் இல் ஸ்டோனி சிற்றாறு பல்கலைக்கழகம் , தேசிய கலைக்கழகம் ஆஃப் அறிவியல் , தேசிய கலைக்கழகம் , ஈகர்ட் வீம்மேர் , ஸ்டோனி சிற்றாறு பல்கலைக்கழகம் , மேற்சுழல் கூட்டாளர்கள் , நோய் கட்டுப்பாடு ,

Codagenix and Serum Institute of India Announce Commencement of First-in-Human Trial of COVI-VAC, A Single Dose, Intranasal Live Attenuated Vaccine for COVID-19

Share this article
Share this article
NEW YORK and PUNE, India, Dec. 14, 2020 /PRNewswire/ Codagenix, Inc., and the Serum Institute of India Pvt. Ltd. (SIIPL) today announced that a Phase 1 clinical trial of COVI-VAC received regulatory approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) and has commenced in London, UK. COVI-VAC is a single-dose intranasal, live attenuated vaccine against SARS-CoV-2, the virus that causes COVID-19, that was shown to be safe and efficacious in preclinical animal studies. COVI-VAC was developed with Codagenix s Synthetic Attenuated Virus Engineering (
SAVE) platform that uses synthetic biology to re-code the genes of viruses into safe and stable vaccines. COVI-VAC is designed to deliver a safe, live attenuated version of SARS-CoV-2 that may induce a more robust immune response and long-lasting cellular immunity against SARS-CoV-2 compared to other vaccines against the virus. ....

United Kingdom , City Of , Johanna Bennett Ingrid Mezo , Steffen Mueller , Mayank Sen , J Robert Coleman , Eckard Wimmer At Stony Brook University , Prnewswire Codagenix Inc , Serum Institute Of India Pvt , National Academy Of Science , Healthcare Products Regulatory Agency , Serum Institute Of India , Codagenix Inc , Serum Institute , Synthetic Attenuated Virus Engineering , Rajeev Dhere , Executive Director , National Academy , Eckard Wimmer , Stony Brook University , Adjuvant Capital , Topspin Partners , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , ஸ்டெஃபென் முல்லர் , மயங்க் சென் ,